Authors


Alessandra Gennari, MD

Latest:

New Combinations With Epirubicin in Advanced Breast Cancer

Several trials have shown that anthracyclines and taxanes can be combined to achieve response rates ranging from 70% to 90%, with complete responses ranging from 19% to 41%. In an attempt to increase the activity while


Alessandro Gronchi, MD

Latest:

The Diagnosis and Management of Retroperitoneal Sarcoma

Retroperitoneal sarcoma is a rare tumor whose diagnosis and management can be challenging and for which management requires a multidisciplinary team.


Alex A. Adjei, MD, PhD

Latest:

Gemcitabine and Pemetrexed Disodium in Treating Breast Cancer

Pemetrexed disodium (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase. This agent is broadly active in a wide


Alex Rubinsteyn, PhD

Latest:

Mutation-Derived Tumor Antigens: Novel Targets in Cancer Immunotherapy

Because of the abundance of promising preclinical and early-phase clinical data, mutation-derived tumor antigens an exciting new class of targets in cancer immunotherapy.


Alex Y. Chang, MD

Latest:

Recent Advances With Chemotherapy for NSCLC: The ECOG Experience

Management of disseminated non-small-cell lung cancer has changed over the past 10 years. Newer agents, such as vinorelbine (Navelbine) and paclitaxel (Taxol), have been shown to modestly improve survival in patients with


Alexander A. Parikh, MD

Latest:

Synopsis of Angiogenesis Inhibitors in Oncology

Angiogenesis is a dynamic process essential for primary tumor growth and metastases. New insights into the basic understanding of the biologic processes responsible for angiogenesis have led to the characterization of potential therapeutic targets. Several strategies for the development of antiangiogenic therapeutic modalities have been employed, including agents that (1) decrease the activity of specific angiogenic factors, (2) decrease the activity of endothelial survival factors, (3) increase the activity of naturally occurring antiangiogenic agents, or (4) indirectly downregulate angiogenic and survival factor activity.


Alexander Burnett, MD

Latest:

Pegylated Liposomal Doxorubicin: Antitumor Activity in Epithelial Ovarian Cancer or Cancers of Peritoneal Origin

After pegylated liposomal doxorubicin (PEG-LD) (Doxil) was shown to be active in ovarian tumors, several trials were developed at the University of Southern California to determine its safety and efficacy in a variety of gynecologic and peritoneal malignancies. Completed phase I and phase II trials have found PEG-LD to be safe and effective in the treatment of platinum- and paclitaxel-refractory epithelial ovarian carcinoma. A new phase II trial is currently underway in similarly refractory patients with ovarian and other related cancers and various degrees of pretreatment. In addition, the efficacy of PEG-LD is being explored in combination with paclitaxel (Taxol), with cisplatin, and with hyperthermia. [ONCOLOGY 11(Suppl 11):38-44, 1997]


Alexander Drilon, MD

Latest:

Update on Newer Non–EGFR-Targeted Agents in Non–Small-Cell Lung Cancer

MSKCC’s Dr. Alexander Drilon highlights other known alterations that are being targeted or being used as biomarkers in non–small-cell lung cancer.


Alexander H. Paterson, MD

Latest:

Docetaxel/Doxorubicin/Cyclophosphamide in the Treatment of Metastatic Breast Cancer

Preliminary results from phase I trials suggest that the use of docetaxel (Taxotere) and doxorubicin (Adriamycin) is a well tolerated and highly active combination regimen for


Alexander Louie, MD, PhD, MSc

Latest:

Role of Stereotactic Ablative Radiotherapy in Early-Stage Lung Cancer

This video examines the role of radiation therapy in early-stage lung cancer and some of the data comparing stereotactic ablative radiotherapy vs surgery in these patients.


Alexander Menter, MD

Latest:

A Woman With Primary Breast Cancer and a Solitary Sternal Metastasis

The patient presented to her primary care physician 3 months prior with an inverted left nipple and a palpable lump that was highly suggestive of neoplasm on mammogram. An ultrasound-guided core biopsy revealed an infiltrating solid-type ductal carcinoma in situ. The estimated size of the mass was approximately 1 cm. She had no symptoms suggestive of metastatic disease.


Alexander Paterson, MD

Latest:

Docetaxel/Doxorubicin/Cyclophosphamide in the Treatment of Metastic Breast Cancer

A pilot phase II study examined the feasibility of 75 mg/m² of docetaxel (Taxotere) in combination with 50 mg/m²of doxorubicin and 500 mg/m² of cyclophosphamide (Cytoxan, Neosar) in the first-line treatment of metastatic breast cancer. This study was designed to evaluate the efficacy and toxicity of the docetaxel/doxorubicin/cyclophosphamide combination both alone and as induction before high-dose chemotherapy, supplemented by autologous peripheral blood stem-cell transplantation.


Alexander R. Gottschalk, MD, PhD

Latest:

ACR Appropriateness Criteria® Postradical Prostatectomy Irradiation in Prostate Cancer

The purpose of this article is to present an updated set of American College of Radiology consensus guidelines formed from an expert panel on the appropriate use of radiation therapy in postprostatectomy prostate cancer.


Alexander Ree, MD

Latest:

Locoregional Recurrence of an HPV-Positive Squamous Cell Carcinoma of the Head and Neck

Locoregional recurrences are a major source of morbidity and mortality for patients with squamous cell carcinomas of the head and neck (HNSCC).


Alexander Riva, MD

Latest:

Docetaxel/Doxorubicin/Cyclophosphamide in the Treatment of Metastic Breast Cancer

A pilot phase II study examined the feasibility of 75 mg/m² of docetaxel (Taxotere) in combination with 50 mg/m²of doxorubicin and 500 mg/m² of cyclophosphamide (Cytoxan, Neosar) in the first-line treatment of metastatic breast cancer. This study was designed to evaluate the efficacy and toxicity of the docetaxel/doxorubicin/cyclophosphamide combination both alone and as induction before high-dose chemotherapy, supplemented by autologous peripheral blood stem-cell transplantation.


Alexander Ross, BS, BSN, RN

Latest:

Influence of Aerobic Exercise on QOL During Prostate Cancer Treatment

In this interview we discuss a study that looked at the effect of an 8-week exercise intervention on treatment side effects for patients with prostate cancer.


Alexander Sedlis, MD

Latest:

Commentary (Sedlis)-Human Papillomaviruses: Their Clinical Significance in the Management of Cervical Carcinoma

Cervical cancer, which has claimed over 4,500 deaths annually in the United States and hundreds of thousands of lives in other parts of the world, is a preventable disease. Most cervical cancers are preceded by a prolonged phase of cervical


Alexander Urquhart, MD

Latest:

A Young Woman With a Small ER-Positive Breast Cancer, a Micrometastatic Axillary Lymph Node, and an Intermediate Oncotype DX Recurrence Score

patient is a 39-year-old premenopausal woman who presents with a new diagnosis of breast cancer to our multidisciplinary second opinion clinic.


Alexander V. Kirichenko, MD, PhD

Latest:

Modulation of Dose Intensity in Aerodigestive Tract Cancers: Strategies to Reduce Toxicity

Advances in diagnostic and therapeutic radiology and a better understanding of cell biology are being applied in practical ways to modulate treatment morbidity. Conformal radiotherapy targets the cancer precisely and can be combined with new systemically administered radiosensitizers.


Alexander V. Prokhorov, MD, PhD

Latest:

Promoting Smoking Cessation Among Cancer Patients: A Behavioral Model

The smoking cessation clinical practice guideline recently published by the Agency for Health Care Policy and Research (AHCPR) summarizes current knowledge on smoking cessation treatments. Among its


Alexandra Colvin

Latest:

Seventy-Year-Old Man With Large Bladder Mass: Diagnostic and Clinical Challenges of an Uncommon Neoplasm

A 70-year-old man presented at our institution for a second opinion regarding diagnosis of a urinary bladder mass. He had a 3-year history of worsening urinary incontinence and urgency, for which he had undergone colonoscopy, as well as testing for prostate issues; all test results were negative.


Alexandra Gangi, MD

Latest:

Neoadjuvant Chemotherapy and Surgical Management of the Axilla in Breast Cancer: A Review of Current Data

This review will discuss the current status of surgical management of the axilla for patients treated with neoadjuvant chemotherapy.


Alexandra L. Hanlon, PhD

Latest:

Evidence for Cure of ‘Young’ Men With Prostate Cancer

A study was undertaken to evaluate the question of cure in "young" men with prostate cancer treated by external-beam radiation. Results in young men (£ 65 years) were compared to older men. Biochemical freedom from failure was examined to 10 years’ follow-up, and hazard functions for failure vs time were reported. Results show that prostate cancer patients are cured by external-beam radiation and that there is no difference in results for young or older men. Few failures occur after 5 years’ follow-up and the percentage cured is similar to that with prostatectomy, with much less morbidity. Appropriate dose is necessary to optimize outcome. [ONCOLOGY 15(5):563-574, 2001]


Alexandra Levine, MD

Latest:

The New Face of Head and Neck Cancer: The HPV Epidemic

This review discusses current paradigms in the diagnosis and management of HPV-OPSCC, and we emphasize pertinent research questions to investigate going forward, including whether to deintensify treatment in these patients.


Alexandra Pohl, MD

Latest:

Targeting Metastatic Colorectal Cancer in 2008: A Long Way From 5-FU

Colorectal cancer is one of the leading causes of cancer-related death worldwide, with almost 20% of all patients presenting with metastatic disease at the time of their diagnosis. The treatment regimens and options of metastatic colorectal cancer have significantly changed in the last 10 years, leading to an improvement of response rates to about 50%, progression-free survival of about 10 months, and overall survival reaching over 2 years.


Alexandra S. Zimmer, MD

Latest:

Defining the IBC Phenotype

Inflammatory breast cancer (IBC) is an aggressive and lethal form of breast cancer. It is also an entity for which no consensus exists regarding its clinical definition. The current nomenclature is considered a misnomer since its clinical presentation is not caused by inflammatory components but mainly by lymphatic obstruction.


Alexandra Stefanovic, MD

Latest:

Rare PTCLs: Treatment Lagging Behind Pathobiologic Advances

Peripheral T-cell lymphomas, or PTCLs, represent an uncommon and biologically heterogeneous group of hematologic malignancies, accounting for less than 10% of all non-Hodgkin lymphomas worldwide, with marked geographic differences. Due to their low prevalence, variable clinical presentation and phenotypic heterogeneity, these lymphomas have historically been difficult to diagnose and categorize. Since the introduction of immunophenotyping and molecular genetic methods, as well as the development of comprehensive classification systems, there have been significant advances in diagnostic accuracy, classification, and our understanding of the biologic behavior of different PTCL subtypes. However, the molecular pathogenesis of most subtypes of PTCL remains incompletely understood, and treatment outcomes with conventional anthracycline-based chemotherapy regimens are generally significantly inferior to those in aggressive B-cell lymphomas.


Alexandra Traverse-glehen, MD, PhD

Latest:

Splenic Marginal Zone Lymphoma: Current Knowledge and Future Directions

In this article, we review the current knowledge on the biological findings, clinical features, and therapeutic approaches for splenic marginal zone lymphoma.


Alexandre Chigaev, PhD

Latest:

Role of Cyclic AMP in Leukemias

In leukemias, cyclic adenosine monophosphate (cAMP) can play a role in cancer cell maturation and can be both pro- and antiapoptotic.


Alexandre De La Taille, MD

Latest:

Molecular Staging of Prostate Cancer: Dream or Reality?

The reverse transcriptase–polymerase chain reaction (RT-PCR) assay is an extremely sensitive technique for the detection of circulating cells expressing prostate-specific antigen (PSA) in prostate cancer patients. This